The Latest Cardiac and Vascular News
KFAR-SABA, Israel & ALISO VIEJO, Calif.–(BUSINESS WIRE)–CathWorks announced that Ramin Mousavi has joined CathWorks as Vice President of Global Marketing & Strategy. Mr. Mousavi, an experienced cardiovascular marketer, will take responsibility for the CathWorks FFRangio™ System U.S. clinical and commercial launch and direct future expansion into other global markets. Mr. Mousavi […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs). This addition was made following completion of the Company’s application to the U.S. Food […]
CALGARY, Alberta, Feb. 25, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB:HMTXF) is pleased to announce that it has received all approvals from UC Davis Health (“UC Davis”) located in Sacramento, California to be the clinical trial site for the Company’s Phase II clinical trial […]
SAN DIEGO, Feb. 24, 2019 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 25 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will remain suspended from quotation at the Company’s request until […]
BEDMINSTER, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer. Dr. Ferguson is a well-recognized, industry leading […]
PARIS and NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced it has completed enrollment in its pharmacokinetic study […]
Basel, February 25, 2019 – Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy. TQJ230 was discovered by Ionis and has been co-developed to […]
BROOKLYN PARK, Minn., Feb. 25, 2019 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Cardiovascular Research Technologies (CRT) meeting held March 2-5, 2019 in Washington, […]
AUSTIN, Texas, Feb. 25, 2019 /PRNewswire/ — The Texas Cardiac Arrhythmia Institute at St. David’s Medical Center recently began enrolling patients to participate in the DIAMOND-AF II clinical trial to examine the effectiveness of the DiamondTemp System in treating patients with persistent atrial fibrillation, or A Fib. A Fib is a type of […]
IRVINE, Calif.–(BUSINESS WIRE)–Nihon Kohden, a U.S. market leader in precision medical products and services, today announced the appointment of Yasuhiro Yoshitake as its new president and CEO. Yoshitake is taking over the helm of the organization from Dr. Wilson P. Constantine, who led the organization from April 2015 to February […]
